In low and middle-income countries, around 17.6 million people each year die of treatable infectious diseases, reproductive health issues, and childhood illnesses. Millions more experience poor quality of life from chronic diseases.
The high costs of developing innovator drugs means that those treatments are often out of reach for least developed and developing countries, and even in developed countries. Affordable generics offer one major solution to this monumental problem. As such, some governments have used compulsory licensing to secure generics, if a voluntary license is not forthcoming.
However, with more patent owners recognizing that market access has shareholder value as well as patient benefits, voluntary licenses are becoming increasingly desirable.
Generics as a Vehicle to Improve Market Access summarises different approaches to providing generics as a route to improve market access and evaluates the impacts of these strategies.
Generics as a Vehicle to Improve Market Access features exclusive perspectives from key people in the field of market access, including representatives from the pharmaceutical and generics industries, consultants specialising in generics and market access, and individuals from independent market access organisations, such as a voluntary licensing model.
The comprehensive report summarises the key issues around this important subject, and provides a wealth of pertinent tables, charts, and data points from sources such as the Access to Medicine Index, as well as a robust set of references, all in one convenient document.
As well as a detailed exploration of ways in which generics can improve market access, the report offers insights into other mechanisms, such as differential pricing and price-cutting, branded generics, distribution and organisational changes, and even drug donations.
Key Report Features
Views from branded and generic Pharma
Latest definitions and data on the needs for expanded market access
Up-to-date look at the impact of the TRIPS agreement
Demonstrated results of generic competition
Examples of compulsory and voluntary licensing agreements
Voluntary licensing models – ViiV Healthcare and Medicines Patent Pool
Impact of expanded access on revenues and R&D
PR impact for branded and generic Pharma
Role of government in securing market access
Other mechanisms for improving market access
Who Would Benefit From This Report?
This report will be of value to senior pharma directors and managers with responsibilities in the following areas:
Business development Marketing, brand and sales management
This report will also benefit charities working in market access, pharma consultancies, Independent voluntary licensing consultancies, state and national legislators and health policy researchers.
Key Questions Answered
Is market access to low cost drugs just a developing world issue?
Which therapeutic areas are most critical?
How does intellectual property affect market access?
Why do generics improve market access?
Why is compulsory licensing needed?
Does expanded access affect revenues and reinvestment into R&D?
What is the PR impact of voluntary licensing?
Which models for improving access will be the most effective?
Receive clear definitions of the key issues (e.g., which countries are “least developed”?)
Gain insights into the perspectives of generics companies and big pharma
Learn about companies who support voluntary licensing agreements
Find out which companies have compulsory and voluntary licensing agreements in place, and for which drugs
Understand the PR value of voluntary licensing and other routes to expanded market access
Review other mechanisms to improve access, such as differentiated pricing
Hear what industry thought-leaders think are the answers to improving market access
For more information kindly visit :
Generics as a Vehicle to Improve Market Access
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Follow us on twitter: http://twitter.com/#!/Sandhya3B